Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVL + HAIC + camrelizumab + apatinib versus ALPPS for hepatocellular carcinoma with insufficient future liver remnant
ChiCTR2500099374Phase 3Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of camrelizumab, Rivoceranib and FOLFOX in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: 1-year event-free survival rate and Incidence of postoperative complications grade III or higher. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranibFOLFOX
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500099374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099374.